• EPZ5676: Potent DOT1L Inhibitor for MLL Leukemia Research

  2026-07-13

  EPZ5676 is a highly potent and selective DOT1L inhibitor with nanomolar activity in MLL-rearranged leukemia models. This article summarizes its molecular mechanism, selectivity, and validated research applications. Evidence from recent studies and product data supports its use in advanced epigenetic and leukemia workflows.

• Alda 1 (SKU B5508): Reliable ALDH2 Activation for Cardiac Re

  2026-07-13

  This article addresses real-world laboratory challenges in ALDH2 activation assays using Alda 1 (SKU B5508). Through scenario-driven Q&A, we explore how Alda 1 enables reproducible, data-backed workflows for cardioprotection, cytotoxicity, and radiation injury models. Bench scientists gain actionable insights on protocol optimization, vendor reliability, and experimental interpretation.

• D-N-Acetylgalactosamine: Technical Guidelines for Brain Glyc

  2026-07-12

  D-N-Acetylgalactosamine (SKU B7904) is a high-purity, water-soluble compound used for glycoprotein constituent analysis in neurological research, especially in workflows requiring precise glycosylation pathway mapping. It is not suitable for protocols needing ethanol solubility or long-term storage of solutions, and strict adherence to handling and storage parameters is essential for reproducibility.

• CHI3L1 Inhibition Restores Amyloid Clearance in Alzheimer’s

  2026-07-10

  The referenced study demonstrates that Compound Z17 (CHI3L1-IN-5) directly inhibits CHI3L1, restoring amyloid-β uptake and lysosomal function in human astrocytes by blocking NF-κB inflammatory signaling. These findings suggest a targeted approach for mitigating neuroinflammation and improving astrocytic clearance mechanisms in Alzheimer’s disease models.

• Metal-Free Carbon Nanozyme Enables Sensitive ALP Detection A

  2026-07-09

  This study introduces a metal-free carbon dot nanozyme platform for highly sensitive and selective colorimetric detection of alkaline phosphatase (ALP) activity. The approach addresses specificity and cytotoxicity concerns of prior nanozyme assays, offering practical advances for metabolic and diagnostic research.

• Tacalcitol Monohydrate: Synthetic Vitamin D3 Analog for Adva

  2026-07-09

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, empowers scientists to precisely modulate gene expression, nerve growth factor induction, and cancer cell behaviors in both dermatological and oncology models. Its reproducibility, low calcemic toxicity, and robust synergy with chemotherapeutics make it indispensable for translational research workflows.

• FAT4 Loss Drives PI3K/AKT-Mediated Ferroptosis Resistance in

  2026-07-08

  This study demonstrates that loss of FAT4 in hepatocellular carcinoma (HCC) activates the PI3K/AKT pathway, promoting tumor growth and resistance to ferroptosis. Pharmacological PI3K/AKT inhibition restores ferroptosis sensitivity, suggesting FAT4 as a biomarker and therapeutic target for overcoming drug resistance in HCC.

• Triptolide (PG490): Enhancing Cancer and Immunology Assays

  2026-07-08

  Triptolide (PG490) delivers nanomolar-precision control over immune and cancer cell signaling, enabling targeted inhibition of IL-2 and NF-κB pathways. This guide details experimental best practices, protocol optimization, and troubleshooting strategies for maximizing Triptolide’s power in advanced cell and animal models.

• Toremifene: Selective Estrogen-Receptor Modulator for Prosta

  2026-07-07

  Toremifene unlocks next-generation experimental control of estrogen receptor signaling in prostate cancer, enabling precise in vitro and in vivo modeling of metastasis-relevant pathways. Its robust inhibition profile, high purity, and proven synergy with emerging mechanistic targets make it indispensable for translational cancer biology. APExBIO’s Toremifene guarantees reproducibility and confidence across hormone-responsive oncology workflows.

• Cyclodextrin-Induced Cholesterol Depletion Inhibits TRPV1 No

  2026-07-07

  This study demonstrates that β-cyclodextrin derivatives suppress TRPV1- and TRPA1-mediated nociceptive behaviors in mice by depleting membrane cholesterol, offering a non-antagonist approach to peripheral analgesia. These findings reveal the functional importance of lipid rafts in TRP channel activation and suggest new strategies for pain modulation.

• Losartan as a Mechanical Microenvironment Modulator in Tumor

  2026-07-06

  Explore how Losartan, a potent angiotensin II receptor antagonist, enables next-generation research into both cardiovascular physiology and tumor microenvironment remodeling. This article uniquely connects Losartan’s vascular and oncology applications, revealing its value for advanced experimental design.

• Gap19: Selective Connexin 43 Hemichannel Blocker in Immune &

  2026-07-06

  Gap19’s selective inhibition of Cx43 hemichannels enables precise dissection of neuroglial and immune signaling without disrupting gap junctions. Its robust validation in models of cerebral ischemia and inflammation-driven macrophage polarization empowers researchers to push the boundaries of neuroprotection and cardiovascular inflammation studies.

• Hierarchical ROS-Responsive Nanoplatform Repairs Macrophages

  2026-07-05

  This study introduces a hierarchically targeted, ROS-responsive nanoparticle-hydrogel system for treating diabetic periodontitis by repairing mitochondrial dysfunction in M1 macrophages. The platform disrupts the ROS-inflammation feedback loop, leading to reduced tissue damage and enhanced bone regeneration, offering a significant therapeutic advance beyond conventional treatment.

• Cyclodextrin-Induced Cholesterol Depletion Modulates TRPV1/T

  2026-07-04

  This study demonstrates that cyclodextrin derivatives reduce pain and neurogenic inflammation by depleting membrane cholesterol and thereby inhibiting TRPV1 and TRPA1 activation. The findings introduce a mechanistically distinct, non-antagonist approach to peripheral analgesia, with implications for sensory neuron desensitization strategies.

• Resiniferatoxin (RTX): Precision TRPV1 Silencing for Transla

  2026-07-03

  Explore how Resiniferatoxin (RTX) enables chemical inactivation of TRPV1, driving next-generation translational research in neuropathic and osteoarthritis pain. This article blends mechanistic rigor, protocol insight, and strategic vision—anchored by recent breakthroughs and actionable guidance for researchers.

413 records 9/28 page Previous Next First page 上5页 678910 下5页 Last page